Physician profile
Jeffrey Tran
NPI 1285098533
$149,612.85
in general payments reported to CMS, 2019-2025
27 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $903 · 2021: $2,194 · 2022: $2,584 · 2023: $2,658 · 2024: $54K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $81K · Consulting Fee: $28K · Travel and Lodging: $14K · Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Entertainment: $217 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $81,300.00 |
| Consulting Fee | $28,162.50 |
| Travel and Lodging | $13,986.86 |
| Food and Beverage | $13,384.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Entertainment | $217.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $113,261.69 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $21,511.89 | 2020-2025 | Cequa, Xelpros, Bromsite |
| Abbvie INC. | $2,931.34 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Glaukos Corporation | $2,640.68 | 2020-2025 | Radius, Idosetr, Radius Xr |
| Alcon Vision LLC | $2,495.01 | 2019-2025 | Rocklatan, Rhopressa, Tryptyr |
| New World Medical,INC. | $1,755.38 | 2021-2025 | Ahmed Glaucoma Valve, Clearpath, Streamline |
| Oyster Point Pharma, INC. | $915.17 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $565.01 | 2024-2025 | Vevye |
| Allergan, INC. | $557.64 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $511.84 | 2020-2025 | Tecnis Iol, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $413.30 | 2021 | |
| Nova Eye, INC. | $388.80 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $359.83 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $190.36 | 2024 | Eq Workplace |
| Abiomed | $146.73 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $130.72 | 2020-2021 | |
| Horizon Therapeutics Plc | $120.34 | 2021 | |
| Medtronic, INC. | $120.00 | 2024 | Intellis Adaptivestim |
| Iridex Corporation | $119.77 | 2020 | |
| Novartis Pharmaceuticals Corporation | $114.29 | 2021-2023 | |
| Biotissue Holdings INC. | $76.83 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $76.12 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $75.40 | 2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.88 | 2020-2021 | |
| Tearlab Corp | $26.69 | 2024 | Scoutpro Osmolarity System |
| Rxsight INC | $23.03 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.